Exhibit 99.1

AMEDISYS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

ISSUES 2018 GUIDANCE

BATON ROUGE, Louisiana (February 27, 2018) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three month period and year ended December 31, 2017.

Three Month Periods Ended December 31, 2017 and 2016

• Net service revenue increased $37.9 million to $404.2 million compared to $366.3 million in 2016.

• Net loss attributable to Amedisys, Inc. of $3.8 million which is inclusive of a $21.4 million reduction in net income as a result of the enactment of H.R. 1 (Tax Cuts and Jobs Act), compared to net income attributable to Amedisys, Inc. of $8.9 million in 2016.

• Net loss attributable to Amedisys, Inc. per diluted share of $0.11 compared to net income attributable to Amedisys, Inc. of $0.26 in 2016.

Adjusted Quarterly Results*

• Adjusted EBITDA of $37.1 million compared to $30.5 million in 2016.

• Adjusted net service revenue of $404.2 million compared to $365.1 million in 2016.

• Adjusted net income attributable to Amedisys, Inc. of $ 19.4 million compared to $15.0 million in 2016.

• Adjusted net income attributable to Amedisys, Inc. per diluted share of $0.56 compared to $0.44 in 2016.

Years Ended December 31, 2017 and 2016

• Net service revenue increased $96.2 million to $1,533.7 million compared to $1,437.4 million in 2016.

• Net income attributable to Amedisys, Inc. of $30.3 million which is inclusive of a $21.4 million reduction in net income as a result of the enactment of H.R. 1 (Tax Cuts and Jobs Act), compared to $37.3 million in 2016.

• Net income attributable to Amedisys, Inc. per diluted share of $0.88 compared to $1.10 in 2016.

Adjusted Year End Results*

• Adjusted EBITDA of $142.2 million compared to $109.9 million in 2016.

• Adjusted net service revenue of $1,540.2 million compared to $1,437.3 million in 2016.

• Adjusted net income attributable to Amedisys, Inc. of $75.9 million compared to $52.2 million in 2016.

• Adjusted net income attributable to Amedisys, Inc. per diluted share of $2.21 compared to $1.55 in 2016.

* See pages 12 and 13 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

Paul B. Kusserow, President and Chief Executive Officer stated, “I am extremely pleased with the results that our team delivered during the fourth quarter and in 2017. We demonstrated solid growth across all three line of business, continued to improve our position as an industry leader in clinical quality and realized the efficiencies that we promised to our stakeholders in early 2016; all of which helped deliver significant increases in revenue, EBITDA and earnings per share. Entering 2018, we remain focused on our four strategic areas of focus: clinical distinction, employer of choice, operational efficiency and driving growth. As a result of our efforts in the last few years, we have a strong balance sheet and will look to deploy capital to expand our businesses and continue our dedication to deliver value to our patients, referral sources, and, ultimately, our shareholders.”

1

2018 Guidance

• Net service revenue is anticipated to be in the range of $1.60 billion to $1.64 billion.

• Adjusted EBITDA is anticipated to be in the range of $158 million to $163 million.

• Adjusted diluted earnings per share is anticipated to be in the range of $2.97 to $3.08 based on an estimated 34.85 million shares outstanding.

This guidance excludes the effects of any future acquisitions, if any are made.

We urge caution in considering the current trends and 2018 guidance disclosed in this press release. The home health and hospice industry is highly competitive and subject to intensive regulations, and trends and guidance are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission (“SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com.

Earnings Call and Webcast Information

Amedisys will host a conference call on Wednesday, February 28, 2018, at 12:00 p.m. ET to discuss its fourth quarter and year end results. To participate on the conference call, please call before 12:00 p.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through March 28, 2018 by dialing (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering conference ID #13676051.

A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com.

Non-GAAP Financial Measures

This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income (loss) attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted net income attributable to Amedisys, Inc., defined as net income (loss) attributable to Amedisys, Inc. excluding certain items; and (4) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

Additional information

Amedisys, Inc. (the “Company”) is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 59,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With 17,900 employees, in 421 care centers in 34 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 369,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.

We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

Forward-Looking Statements

When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and

2

uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the healthcare industry, our ability to integrate our personal care segment into our business efficiently, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to comply with requirements stipulated in our corporate integrity agreement and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Contact:	Investor Contact:	Media Contact:
	Amedisys, Inc.	Amedisys, Inc.
	David Castille	Kendra Kimmons
	Managing Director, Treasury/Finance	Vice President, Marketing & Communications
	(855) 259-2046	(225) 299-3720
	IR@amedisys.com	kendra.kimmons@amedisys.com

3

AMEDISYS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF OPERATIONS

(Amounts in thousands, except per share data)

	For the Three Month Period Ended December 31,						For the Year Ended December 31,
	2017			2016			2017			2016
	(Unaudited)
Net service revenue	$	404,238		$	366,296		$	1,533,680		$	1,437,454
Cost of service, excluding depreciation and amortization		238,534			212,589			900,726			833,055
General and administrative expenses:
Salaries and benefits		79,406			75,902			305,938			306,981
Non-cash compensation		4,507			3,845			16,295			16,401
Other		39,757			45,097			159,980			180,048
Provision for doubtful accounts		6,981			5,855			25,059			19,519
Depreciation and amortization		3,984			5,016			17,123			19,678
Asset impairment charge		1,323			4,432			1,323			4,432
Securities Class Action Lawsuit settlement, net		—			—			28,712			—
Operating expenses		374,492			352,736			1,455,156			1,380,114
Operating income		29,746			13,560			78,524			57,340
Other income (expense):
Interest income		54			30			158			75
Interest expense		(1,431	)		(1,613	)		(5,031	)		(5,164	)
Equity in earnings from equity method investments		232			1,986			3,381			5,588
Miscellaneous, net		487			621			3,769			3,727
Total other income (expense), net		(658	)		1,024			2,277			4,226
Income before income taxes		29,088			14,584			80,801			61,566
Income tax expense		(32,794	)		(5,612	)		(50,118	)		(23,935	)
Net income (loss)		(3,706	)		8,972			30,683			37,631
Net income attributable to noncontrolling interests		(142	)		(55	)		(382	)		(370	)
Net income (loss) attributable to Amedisys, Inc.	$	(3,848	)	$	8,917		$	30,301		$	37,261
Basic earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders	$	(0.11	)	$	0.27		$	0.90		$	1.12
Weighted average shares outstanding		33,898			33,365			33,704			33,198
Diluted earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders	$	(0.11	)	$	0.26		$	0.88		$	1.10
Weighted average shares outstanding		33,898			33,866			34,304			33,741

4

AMEDISYS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEET

(Amounts in thousands, except share data)

	December 31, 2017			December 31, 2016
ASSETS
Current assets:
Cash and cash equivalents	$	86,363		$	30,197
Patient accounts receivable, net of allowance for doubtful accounts of $20,866 and $17,716		201,196			166,056
Prepaid expenses		7,329			7,397
Other current assets		16,268			11,260
Total current assets		311,156			214,910
Property and equipment, net of accumulated depreciation of $146,814 and $138,650		31,122			36,999
Goodwill		319,949			288,957
Intangible assets, net of accumulated amortization of $30,610 and $27,864		46,061			46,755
Deferred income taxes		56,064			107,940
Other assets, net		49,130			38,468
Total assets	$	813,482		$	734,029
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	25,384		$	30,358
Payroll and employee benefits		89,936			82,480
Accrued expenses		89,104			63,290
Current portion of long-term obligations		10,638			5,220
Total current liabilities		215,062			181,348
Long-term obligations, less current portion		78,203			87,809
Other long-term obligations		3,791			3,730
Total liabilities		297,056			272,887
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding		—			—
Common stock, $0.001 par value, 60,000,000 shares authorized; 35,747,134 and 35,253,577 shares issued; and 33,964,767 and 33,597,215 shares outstanding		35			35
Additional paid-in capital		568,780			537,472
Treasury stock at cost, 1,782,367 and 1,656,362 shares of common stock		(53,713	)		(46,774	)
Accumulated other comprehensive income		15			15
Retained earnings (deficit)		204			(30,545	)
Total Amedisys, Inc. stockholders’ equity		515,321			460,203
Noncontrolling interests		1,105			939
Total equity		516,426			461,142
Total liabilities and equity	$	813,482		$	734,029

5

AMEDISYS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING, NET

(Amounts in thousands, except statistical information)

	For the Three Month Period Ended December 31,						For the Year Ended December 31,
	2017			2016			2017			2016
	(Unaudited)
Cash Flows from Operating Activities:
Net income (loss)	$	(3,706	)	$	8,972		$	30,683		$	37,631
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		3,984			5,016			17,123			19,678
Provision for doubtful accounts		6,981			5,855			25,059			19,519
Non-cash compensation		4,507			3,845			16,295			16,401
401(k) employer match		2,207			1,741			8,754			6,875
Write-off of investment		—			196			—			196
Loss on disposal of property and equipment		22			26			—			582
Deferred income taxes		34,950			5,858			52,178			24,547
Equity in earnings from equity method investments		(232	)		(1,986	)		(3,381	)		(5,588	)
Amortization of deferred debt issuance costs		180			185			735			740
Return on equity investment		665			2,410			5,321			4,323
Asset impairment charge		1,323			4,432			1,323			4,432
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable		(30,807	)		(9,412	)		(59,731	)		(55,519	)
Other current assets		956			3,361			(4,940	)		4,231
Other assets		(547	)		494			(12,749	)		(11,415	)
Accounts payable		2,587			(3,338	)		(2,843	)		3,970
Accrued expenses		9,259			1,482			31,843			(7,618	)
Other long-term obligations		(140	)		(576	)		61			(726	)
Net cash provided by operating activities		32,189			28,561			105,731			62,259
Cash Flows from Investing Activities:
Proceeds from sale of deferred compensation plan assets		—			—			622			230
Proceeds from sale of property and equipment		131			—			249			—
Purchases of property and equipment		(1,633	)		(2,215	)		(10,707	)		(15,717	)
Purchase of investments		(40	)		(290	)		(476	)		(1,040	)
Acquisitions of businesses, net of cash acquired		(9,587	)		(4,144	)		(33,715	)		(35,522	)
Net cash used in investing activities		(11,129	)		(6,649	)		(44,027	)		(52,049	)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options and warrants		340			—			4,554			—
Proceeds from issuance of stock to employee stock purchase plan		584			665			2,382			2,483
Shares withheld upon stock vesting		(485	)		—			(6,939	)		—
Tax benefit from stock options exercised and restricted stock vesting		—			—			—			7,241
Non-controlling interest distribution		—			(45	)		(216	)		(329	)
Proceeds from revolving line of credit		—			6,000			—			134,500
Repayments of revolving line of credit		—			(6,000	)		—			(134,500	)
Principal payments of long-term obligations		(1,250	)		(1,250	)		(5,319	)		(5,000	)
Purchase of company stock		—			—			—			(12,315	)
Assets contributed to equity investment		—			—			—			405
Net cash used in financing activities		(811	)		(630	)		(5,538	)		(7,515	)
Net increase in cash and cash equivalents		20,249			21,282			56,166			2,695
Cash and cash equivalents at beginning of period		66,114			8,915			30,197			27,502
Cash and cash equivalents at end of period	$	86,363		$	30,197		$	86,363		$	30,197
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$	509		$	621		$	2,697		$	2,897
Cash paid for income taxes, net of refunds received	$	—		$	(3	)	$	315		$	755
Days revenue outstanding, net (1)		44.0			40.2			44.0			40.2

(1) Our calculation of days revenue outstanding, net at December 31, 2017 and 2016 is derived by dividing our ending patient accounts receivable (i.e., net of estimated revenue adjustments and allowance for doubtful accounts) by our average daily net patient revenue for the three month periods ended December 31, 2017 and 2016, respectively.

6

AMEDISYS, INC. AND SUBSIDIARIES

SEGMENT INFORMATION

(Amounts in millions, except statistical information)

(Unaudited)

Segment Information - Home Health        

	For the Three Month Period Ended December 31,
	2017			2016
Financial Information (in millions):
Medicare	$	205.0		$	203.2
Non-Medicare		82.3			65.1
Net service revenue		287.3			268.3
Cost of service		174.9			160.1
Gross margin		112.4			108.2
Provision for doubtful accounts		5.4			3.1
Asset impairment charge		1.3			—
Other operating expenses		71.3			69.6
Operating income	$	34.4		$	35.5
Same Store Growth (1):
Medicare revenue		2	%		(1	%)
Non-Medicare revenue		26	%		(2	%)
Medicare admissions		(2	%)		2	%
Total Episodic admissions		2	%		4	%
Total Episodic volume		5	%		3	%
Total admissions		3	%		-	%
Key Statistical Data - Total (2):
Medicare:
Admissions		46,421			47,637
Recertifications		27,896			25,628
Total volume		74,317			73,265
Completed episodes		73,037			71,855
Visits		1,273,435			1,230,434
Average revenue per completed episode (3)	$	2,858		$	2,851
Visits per completed episode (4)		17.6			17.2
Non-Medicare:
Admissions		27,421			24,309
Recertifications		12,415			9,673
Visits		619,745			501,215
Total (2):
Visiting Clinician Cost per Visit	$	83.88		$	83.46
Clinical Manager Cost per Visit	$	8.49		$	9.01
Total Cost per Visit	$	92.37		$	92.47
Visits		1,893,180			1,731,649

7

	For the Year Ended December 31,
	2017			2016
Financial Information (in millions):
Medicare	$	793.3		$	822.4
Non-Medicare		308.5			263.1
Net service revenue		1,101.8			1,085.5
Cost of service		670.9			643.7
Gross margin		430.9			441.8
Provision for doubtful accounts		17.9			13.8
Asset impairment charge		1.3			—
Other operating expenses		281.9			289.4
Operating income	$	129.8		$	138.6
Same Store Growth (1):
Medicare revenue		(4	%)		2	%
Non-Medicare revenue		17	%		8	%
Medicare admissions		(2	%)		3	%
Total Episodic admissions		1	%		4	%
Total Episodic volume		3	%		3	%
Total admissions		2	%		2	%
Key Statistical Data - Total (2):
Medicare:
Admissions		190,132			194,662
Recertifications		106,774			103,193
Total volume		296,906			297,855
Completed episodes		290,227			289,862
Visits		5,067,436			5,124,002
Average revenue per completed episode (3)	$	2,823		$	2,839
Visits per completed episode (4)		17.3			17.5
Non-Medicare:
Admissions		107,665			98,448
Recertifications		46,364			38,618
Visits		2,347,363			2,050,975
Total (2):
Visiting Clinician Cost per Visit	$	82.04		$	81.18
Clinical Manager Cost per Visit	$	8.44		$	8.53
Total Cost per Visit	$	90.48		$	89.71
Visits		7,414,799			7,174,977

(1) Same store information represents the percent increase (decrease) in our Medicare and Non-Medicare revenue, admissions or volume for the period as a percent of the Medicare and Non-Medicare revenue, admissions or volume of the prior period.

(2) Total includes acquisitions.

(3) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.

(4) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.

8

Segment Information - Hospice     

	For the Three Month Period Ended December 31,
	2017			2016
Financial Information (in millions):
Medicare	$	92.7		$	80.7
Non-Medicare		5.5			4.5
Net service revenue		98.2			85.2
Cost of service		49.9			43.0
Gross margin		48.3			42.2
Provision for doubtful accounts		1.0			2.7
Other operating expenses		20.8			18.7
Operating income	$	26.5		$	20.8
Same Store Growth (1):
Medicare revenue		14	%		14	%
Non-Medicare revenue		20	%		(7	%)
Hospice admissions		8	%		16	%
Average daily census		12	%		13	%
Key Statistical Data - Total (2):
Hospice admissions		6,371			5,769
Average daily census		7,162			6,318
Revenue per day, net	$	149.12		$	146.56
Cost of service per day	$	75.74		$	73.91
Average discharge length of stay		96			99
	For the Year Ended December 31,
	2017			2016
Financial Information (in millions):
Medicare	$	350.7		$	297.7
Non-Medicare		20.3			18.3
Net service revenue		371.0			316.0
Cost of service		184.8			163.1
Gross margin		186.2			152.9
Provision for doubtful accounts		5.9			5.5
Other operating expenses		77.5			71.5
Operating income	$	102.8		$	75.9
Same Store Growth (1):
Medicare revenue		17	%		15	%
Non-Medicare revenue		10	%		9	%
Hospice admissions		11	%		17	%
Average daily census		15	%		16	%
Key Statistical Data -Total (2):
Hospice admissions		25,381			22,526
Average daily census		6,820			5,912
Revenue per day, net	$	149.04		$	146.05
Cost of service per day	$	74.25		$	75.36
Average discharge length of stay		93			96

(1) Same store information represents the percent increase (decrease) in our Medicare and Non-Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare and Non-Medicare revenue, Hospice admissions or average daily census of the prior period.

(2) Total includes acquisitions.

9

Segment Information - Personal Care         

	For the Three Month Period Ended December 31,
	2017		2016
Financial Information (in millions):
Medicare	$	—	$	—
Non-Medicare		18.7		12.7
Net service revenue		18.7		12.7
Cost of service		13.7		9.5
Gross margin		5.0		3.2
Provision for doubtful accounts		0.6		0.1
Other operating expenses		4.4		2.8
Operating income	$	0.0	$	0.3
Key Statistical Data:
Billable hours		782,140		548,703
Clients served		12,693		7,392
Shifts		365,360		245,535
Revenue per hour	$	23.94	$	23.16
Revenue per shift	$	51.26	$	51.75
Hours per shift		2.1		2.2
	For the Year Ended December 31,
	2017		2016
Financial Information (in millions):
Medicare	$	—	$	—
Non-Medicare		60.9		35.9
Net service revenue		60.9		35.9
Cost of service		45.0		26.3
Gross margin		15.9		9.6
Provision for doubtful accounts		1.3		0.2
Other operating expenses		13.8		7.9
Operating income	$	0.8	$	1.5
Key Statistical Data:
Billable hours		2,604,794		1,539,093
Clients served		16,826		10,219
Shifts		1,195,511		696,956
Revenue per hour	$	23.37	$	23.32
Revenue per shift	$	50.92	$	51.49
Hours per shift		2.2		2.2

10

Segment Information - Corporate

	For the Three Month Period Ended December 31,
	2017		2016
Financial Information (in millions):
Other operating expenses	$	28.3	$	35.5
Depreciation and amortization		2.9		3.1
Total operating expenses before asset impairment charge		31.2		38.6
Asset impairment charge		—		4.4
Total operating expenses	$	31.2	$	43.0
	For the Year Ended December 31,
	2017		2016
Financial Information (in millions):
Other operating expenses	$	113.7	$	141.9
Depreciation and amortization		12.5		12.4
Total operating expenses before asset impairment charge and Securities Class Action Lawsuit settlement, net		126.2		154.3
Asset impairment charge		—		4.4
Securities Class Action Lawsuit settlement, net		28.7		—
Total operating expenses	$	154.9	$	158.7

11

AMEDISYS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES

(Amounts in thousands)

(Unaudited)

Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”):

	For the Three Month Period Ended December 31,						For the Year Ended December 31,
	2017			2016			2017			2016
Net income (loss) attributable to Amedisys, Inc.	$	(3,848	)	$	8,917		$	30,301		$	37,261
Add:
Income tax expense		32,794			5,612			50,118			23,935
Interest expense, net		1,377			1,583			4,873			5,089
Depreciation and amortization		3,984			5,016			17,123			19,678
Certain items (1)		24,414			9,999			61,429			24,559
Interest component of certain items (1)		(168	)		(625	)		(263	)		(625	)
Tax component of certain items (1)		(21,424	)		—			(21,424	)		—
Adjusted EBITDA (2) (6)	$	37,129		$	30,502		$	142,157		$	109,897

Adjusted Net Service Revenue Reconciliation:

	For the Three Month Period Ended December 31,					For the Year Ended December 31,
	2017		2016			2017		2016
Net service revenue	$	404,238	$	366,296		$	1,533,680	$	1,437,454
Add:
Certain items (1)		—		(1,149	)		6,506		(201	)
Adjusted net service revenue (3) (6)	$	404,238	$	365,147		$	1,540,186	$	1,437,253

Adjusted Net Income Attributable to Amedisys, Inc. Reconciliation:    

	For the Three Month Period Ended December 31,					For the Year Ended December 31,
	2017			2016		2017		2016
Net income (loss) attributable to Amedisys, Inc.	$	(3,848	)	$	8,917	$	30,301	$	37,261
Add:
Certain items (1)		23,233			6,114		45,627		14,923
Adjusted net income attributable to Amedisys, Inc. (4) (6)	$	19,385		$	15,031	$	75,928	$	52,184

Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share:    

	For the Three Month Period Ended December 31,					For the Year Ended December 31,
	2017			2016		2017		2016
Net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share	$	(0.11	)	$	0.26	$	0.88	$	1.10
Add:
Certain items (1)		0.67			0.18		1.33		0.44
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share (5) (6)	$	0.56		$	0.44	$	2.21	$	1.55

(1) The following details the certain items for the three month periods and years ended December 31, 2017 and 2016:

12

Certain Items:    

	For the Three Month Period Ended December 31, 2017			For the Year Ended December 31, 2017
	(Income) Expense			(Income) Expense
Certain Items Impacting Net Service Revenue:
Florida ZPIC audit	$	—		$	6,506
Certain Items Impacting Operating Expenses:
Acquisition costs		48			1,025
Legal fees - non-routine		358			1,768
Securities Class Action Lawsuit settlement, net		—			28,712
Restructuring activity		648			2,318
Data center relocation		—			940
Asset impairment		1,323			1,323
Certain Items Impacting Total Other Income (Expense):
Legal settlements		—			(2,014	)
Miscellaneous, other (income) expense, net		613			(573	)
Certain Items Impacting Income Tax Expense:
Remeasurement of deferred tax assets and liabilities		21,424			21,424
Total	$	24,414		$	61,429
Net of tax	$	23,233		$	45,627
Diluted EPS	$	0.67		$	1.33
	For the Three Month Period Ended December 31, 2016			For the Year Ended December 31, 2016
	(Income) Expense			(Income) Expense
Certain Items Impacting Net Service Revenue:
Reduction of cost report reserve	$	(1,149	)	$	(1,149	)
Third party audit reserve		—			948
Certain Items Impacting Operating Expenses:
HCHB implementation		1,345			8,371
Acquisition costs		876			3,384
Legal fees - non-routine		543			1,992
Frontier litigation		2,479			2,979
Wage and Hour litigation		(119	)		282
Asset impairment		4,432			4,432
Restructuring activity		1,976			7,645
Sales/use tax audit reserve		460			460
Disaster relief		129			467
Certain Items Impacting Total Other Income (Expense):
Sales/use tax audit reserve		625			625
Legal settlements		(280	)		(2,328	)
Miscellaneous, other (income) expense, net		(1,318	)		(3,549	)
Total	$	9,999		$	24,559
Net of tax	$	6,114		$	14,923
Diluted EPS	$	0.18		$	0.44

(2) Adjusted EBITDA is defined as net income (loss) attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items as described in footnote 1.

(3) Adjusted net service revenue is defined as net service revenue plus certain items as described in footnote 1.

(4) Adjusted net income attributable to Amedisys, Inc. is defined as net income (loss) attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.

(5) Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income (loss) per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.

(6) Adjusted EBITDA, adjusted net service revenue, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measure calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.

13